利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

15 records (took 0.014 seconds)

    METHODS
    1.
    发明申请
    METHODS 审中-公开
    方法

    公开(公告)号：WO2010084327A3

    公开(公告)日：2010-09-23

    申请号：PCT/GB2010000107

    申请日：2010-01-26

    Applicant: ELECTROPHORETICS LTD ,  KING S COLLEGE LONDON ,  LOVESTONE SIMON HAROLD ,  CAMPBELL JAMES ,  O'BRIEN DARRAGH PATRICK WILLIAM ,  GUENTERT ANDREAS CHRISTIAN ,  BYERS HELEN LOUISE

    Inventor： LOVESTONE SIMON HAROLD ,  CAMPBELL JAMES ,  O'BRIEN DARRAGH PATRICK WILLIAM ,  GUENTERT ANDREAS CHRISTIAN ,  BYERS HELEN LOUISE

    IPC: G01N33/68

    CPC classification number: G01N33/6896 ,  G01N2800/2821

    Abstract: The invention provides a method for aiding the diagnosis or prognostic monitoring of Alzheimer's disease in a subject, said method comprising; providing a sample of blood obtained from said patient; assaying the amount of gelsolin present in said sample; comparing the amount of gelsolin present in said sample to a reference amount of gelsolin present in a sample from a healthy subject,, wherein detection of a gelsolin level in the sample from said patient which is lower than the gelsolin level in the reference sample indicates an increased likelihood of Alzheimer's disease in said patient. Other markers are Cl protease inhibitor and ceruloplasmin. Both blood samples and tissue samples have been investigated.

    Abstract translation: 本发明提供了一种帮助受试者中阿尔茨海默病的诊断或预后监测的方法，所述方法包括： 提供从所述患者获得的血液样品; 测定所述样品中存在的凝溶胶蛋白的量; 将所述样品中存在的凝溶胶蛋白的量与来自健康受试者的样品中存在的参考量的凝溶胶蛋白进行比较，其中来自所述患者的样品中的凝溶胶蛋白水平低于参考样品中的凝溶胶蛋白水平，表明 在所述患者中增加阿尔茨海默病的可能性。 其他标记物是Cl蛋白酶抑制剂和血浆铜蓝蛋白。 血液样本和组织样本均已被调查。

    MASS LABELS
    6.
    发明申请
    MASS LABELS 审中-公开
    质量标签

    公开(公告)号：WO2011036059A1

    公开(公告)日：2011-03-31

    申请号：PCT/EP2010/063191

    申请日：2010-09-08

    Applicant: ELECTROPHORETICS LIMITED ,  BAUMANN, Christian ,  BYERS, Helen ,  SCHULZ-KNAPPE, Peter ,  WARD, Malcolm

    Inventor： BAUMANN, Christian ,  BYERS, Helen ,  SCHULZ-KNAPPE, Peter ,  WARD, Malcolm

    IPC: C07B59/00 ,  C07D211/14 ,  C07D401/12

    CPC classification number: G01N33/743 ,  C07B59/002 ,  C07D211/14 ,  C07D401/12 ,  G01N33/58 ,  G01N2458/15 ,  G01N2560/00 ,  Y10T436/196666 ,  Y10T436/200833 ,  Y10T436/24

    Abstract: A reactive mass label for labelling a biological molecule for detection by mass spectrometry, which label comprises a reactive functionality for labelling thiol groups or carbonyl groups. Also provided is a reactive mass label for labelling a biological molecule for detection by mass spectrometry, wherein the mass label comprises the following structure: X-L-M-S-Re wherein X is a mass marker moiety, L is a cleavable linker, M is a mass normalization moiety, S is a mass series modifying group comprising the following group: Formula (I), wherein J is C=O, K is NH, and n is 2 or J and K are both CH2 and n is 1, and wherein m is at least 1; and Re is a reactive functionality for attaching the mass label to a biological molecule.

    Abstract translation: 用于通过质谱法标记用于检测的生物分子的反应性质量标签，该标记包括用于标记巯基或羰基的反应性官能团。 还提供了用于通过质谱法标记用于检测的生物分子的反应性质量标签，其中所述质量标签包含以下结构：XLMS-Re，其中X是质量标记物部分，L是可切割接头，M是质量归一化部分 S是包含以下基团的质量系列改性基团：式（I）其中J为C = O，K为NH，n为2或J和K均为CH 2，n为1，m为 至少1; 并且Re是用于将质量标签附着到生物分子的反应性官能团。

    DIAGNOSIS OF NEURODEGENERATIVE DISEASES
    7.
    发明申请
    DIAGNOSIS OF NEURODEGENERATIVE DISEASES 审中-公开
    诊断神经源性疾病

    公开(公告)号：WO2006061610A2

    公开(公告)日：2006-06-15

    申请号：PCT/GB2005/004700

    申请日：2005-12-07

    Applicant: ELECTROPHORETICS LIMITED ,  UNIVERSITY COLLEGE LONDON ,  MEDICAL RESEARCH COUNCIL ,  LEEDS, Nicola, Louise ,  WARD, Malcolm, Andrew ,  McGREGOR, Emma ,  TABRIZI, Sarah, Joanna ,  DALRYMPLE, Annette ,  CAMPBELL, James ,  WESTBROKE, Julian, Arthur ,  BYERS, Helen, Louise

    Inventor： LEEDS, Nicola, Louise ,  WARD, Malcolm, Andrew ,  McGREGOR, Emma ,  TABRIZI, Sarah, Joanna ,  DALRYMPLE, Annette ,  CAMPBELL, James ,  WESTBROKE, Julian, Arthur ,  BYERS, Helen, Louise

    IPC: G01N33/68

    CPC classification number: G01N33/6896 ,  G01N2800/52

    Abstract: The invention relates to a method of diagnosis of Huntington's Disease in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an altered concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being selected from: Swiss Prot accession number : Protein name; P10909 : Clusterin precursor; P00738 : Haptoglobin precursor; P01009 : Alpha- l-antitrypsin precursor; P01024 : Complement C3 precursor; P01620 : 1g kappa chain V-III region; P01834 : 1g kappa chain C region P01842 : 1g lambda chain C regions; P01857 : 1g gamma-1 chain C region; P01859 : Ig gamma-2 chain C region; P01876 : 1g alpha-1 chain C region P02647 : Apolipoprotein A-I precursor; P02649 : Apolipoprotein E precursor; P02652 : Apolipoprotcin A-II precursor; P02655 : Apolipoprotein C-II precursor; P02656 : Apolipoprotein C-III precursor P02671 : Fibrinogen alpha/alpha-E chain precursor; P02763 : Alpha- l-acid glycoprotein 1 precursor; P02766 : Transthyretin precursor; P02768 : Serum albumin precursor; P02787 : Serotransferrin precursor; P04196 : Histidine-rich glycoprotein precursor; P06727 : Apolipoprotein A-IV precursor; P19652 : Alpha- l-acid glycoprotein 2 precursor; P68871/P02042 : Hemoglobin beta chain/Hemoglobin delta chain; P60709 : Beta actin.

    Abstract translation: 本发明涉及一种在人受试者的有效身体组织的诊断样本中诊断亨廷顿病的方法，其包括检测诊断样品中蛋白质的浓度变化，与对照人受试者的样品相比， 该蛋白质选自：瑞士抗原登录号：蛋白质名称; P10909：聚集蛋白前体; P00738：近红球蛋白前体; P01009：α-抗胰蛋白酶前体; P01024：补体C3前体; P01620：1gκ链V-III区; P01834：1gκ链C区P01842：1gλ链C区; P01857：1gγ-1链C区; P01859：Igγ-2链C区; P01876：1gα-1链C区P02647：载脂蛋白A-1前体; P02649：载脂蛋白E前体; P02652：载脂蛋白A-II前体; P02655：载脂蛋白C-II前体; P02656：载脂蛋白C-III前体P02671：纤维蛋白原α/α-E链前体; P02763：α-酸性糖蛋白1前体; P02766：曲氨酸蛋白前体; P02768：血清白蛋白前体; P02787：血清转铁蛋白前体; P04196：富含组氨酸糖蛋白前体; P06727：载脂蛋白A-IV前体; P19652：α-酸性糖蛋白2前体; P68871 / P02042：血红蛋白β链/血红蛋白三角链; P60709：β肌动蛋白

    MASS SPECTROMETRIC ANALYSIS
    8.
    发明申请
    MASS SPECTROMETRIC ANALYSIS 审中-公开
    质谱分析

    公开(公告)号：WO2009141310A1

    公开(公告)日：2009-11-26

    申请号：PCT/EP2009/056010

    申请日：2009-05-18

    Applicant: ELECTROPHORETICS LIMITED ,  BAUMANN, Christian ,  BYERS, Helen ,  SCHULZ-KNAPPE, Peter ,  WARD, Malcolm

    Inventor： BAUMANN, Christian ,  BYERS, Helen ,  SCHULZ-KNAPPE, Peter ,  WARD, Malcolm

    IPC: G01N33/68

    CPC classification number: G01N33/6848 ,  Y10T436/143333

    Abstract: A method for assaying for a target analyte, which method comprises: (a) providing a plurality of samples which may comprise the target analyle, wherein each sample is differentially labelled with a mass label or a combination of mass labels, wherein the mass labels are from a set of mass labels, wherein each mass label is an isobaric mass label comprising a mass spectrometrically distinct mass marker group, such that the samples can be distinguished by mass spectrometry; (b) mixing the plurality of labelled samples to produce an analysis mixture and introducing the analysis mixture into a mass spectrometer; (c) selecting ions having a first mass to charge ratio equivalent to an ion of the target analyte labelled with a specific number of mass labels; (d) fragmenting ions of the first mass to charge ratio into a plurality of fragment ions, wherein a proportion of the plurality of fragment ions comprise at least one intact mass label; (e) selecting ions of a second mass to charge ratio equivalent to an ion of a fragment of the target analyte comprising at least one intact mass label; (f) fragmenting ions of the second mass to charge ratio into a plurality of further fragment ions, wherein a proportion of the further fragment ions are ions of the mass marker groups; (g) producing a mass spectrum of the further fragment ions produced in step (f); and (h) determining from the mass spectrum the quantity of the target analyte in each sample.

    Abstract translation: 一种用于测定目标分析物的方法，所述方法包括：（a）提供可包含靶分析物的多个样品，其中每个样品用质量标签或质量标签的组合差异标记，其中质量标签为 来自一组质量标签，其中每个质量标签是包含质谱分辨率不同的质量标记物组的等压质量标签，使得样品可以通过质谱鉴别; （b）混合多个标记的样品以产生分析混合物并将分析混合物引入质谱仪中; （c）选择具有与用特定数量的质量标签标记的目标分析物的离子相当的第一质荷比的离子; （d）将所述第一质荷比的离子分散成多个碎片离子，其中所述多个碎片离子的一部分包含至少一个完整质量标签; （e）选择与包含至少一个完整质量标签的目标分析物的片段的离子相当的第二质量与充电比的离子; （f）将第二质荷比的离子分散成多个另外的碎片离子，其中一部分另外的碎片离子是质量标记物组的离子; （g）产生步骤（f）中产生的另外的碎片离子的质谱; 和（h）从质谱确定每个样品中的目标分析物的量。

    DIAGNOSIS OF NEURODEGENERATIVE DISEASES
    9.
    发明申请
    DIAGNOSIS OF NEURODEGENERATIVE DISEASES 审中-公开
    诊断神经源性疾病

    公开(公告)号：WO2006061609A3

    公开(公告)日：2006-09-08

    申请号：PCT/GB2005004698

    申请日：2005-12-07

    Applicant: ELECTROPHORETICS LTD ,  MEDICAL RES COUNCIL ,  UNIV LONDON ,  WARD MALCOLM ANDREW ,  COLLINGE JOHN ,  JACKSON GRAHAM STUART ,  MCGREGOR EMMA ,  LEEDS NICOLA LOUISE ,  CAMPBELL JAMES ,  WESTBROOK JULES ARTHUR ,  BYERS HELEN LOUISE

    Inventor： WARD MALCOLM ANDREW ,  COLLINGE JOHN ,  JACKSON GRAHAM STUART ,  MCGREGOR EMMA ,  LEEDS NICOLA LOUISE ,  CAMPBELL JAMES ,  WESTBROOK JULES ARTHUR ,  BYERS HELEN LOUISE

    IPC: G01N33/68

    CPC classification number: G01N33/6896 ,  G01N2800/52

    Abstract: The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Ace. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Ace. No. P02023); or alpha-1-antitrypsin (SwissProt Ace. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Ace. No. P51884); alpha-fibrinogen precursor (SwissProt Ace. No. P02671); IGHG4 protein (Swiss Prot Ace. No. Q8TC63) or immunoglobulin lambda heavy chain. Other marker proteins are also disclosed.

    Abstract translation: 本发明涉及一种诊断样品中vCJD的方法，该方法是从人体受试者获取的有效身体组织的诊断样本中，其与检测样本中的蛋白质的浓度相比较，与对照人受试者相比， 蛋白质是：β-肌动蛋白（SwissProt Ace.No.P60709），载脂蛋白A-IV前体（SwissProt Acc.Po6727）; 由残基162-406组成的触珠蛋白β链（SwissProt Acc.P00738）; 血红蛋白β链（SwissProt Ace。编号P02023）; 或α-1-抗胰蛋白酶（SwissProt Ace.Po1009）; 或与对照组，正常人受试者的样品，蛋白质是血浆蛋白酶（C1）抑制剂前体（SwissProt Acc.No.P05155））相比，诊断样品中蛋白质的浓度降低。 补充成分1的子成分（SwissProt Acc。No.P09871）; 丁酰胆碱酯酶前体（SwissProt Acc.Po6276）; 补体成分C4B（SwissProt Acc。No.P01028）; lumican（SwissProt Ace。No. P51884）; α-纤维蛋白原前体（SwissProt Ace。编号P02671）; IGHG4蛋白（Swiss Prot Ace。No.Q8TC63）或免疫球蛋白λ重链。 还公开了其它标记蛋白。

    DIAGNOSIS OF NEURODEGENERATIVE DISEASES
    10.
    发明申请
    DIAGNOSIS OF NEURODEGENERATIVE DISEASES 审中-公开
    神经退行性疾病的诊断

    公开(公告)号：WO2006061609A2

    公开(公告)日：2006-06-15

    申请号：PCT/GB2005/004698

    申请日：2005-12-07

    Applicant: ELECTROPHORETICS LIMITED ,  MEDICAL RESEARCH COUNCIL ,  UNIVERSITY COLLEGE LONDON ,  WARD, Malcolm, Andrew ,  COLLINGE, John ,  JACKSON, Graham, Stuart ,  MCGREGOR, Emma ,  LEEDS, Nicola, Louise ,  CAMPBELL, James ,  WESTBROOK, Jules ,  BYERS, Helen

    Inventor： WARD, Malcolm, Andrew ,  COLLINGE, John ,  JACKSON, Graham, Stuart ,  MCGREGOR, Emma ,  LEEDS, Nicola, Louise ,  CAMPBELL, James ,  WESTBROOK, Jules ,  BYERS, Helen

    IPC: G01N33/68

    CPC classification number: G01N33/6896 ,  G01N2800/52

    Abstract: The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Ace. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Ace. No. P02023); or alpha-1-antitrypsin (SwissProt Ace. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Ace. No. P51884); alpha-fibrinogen precursor (SwissProt Ace. No. P02671); IGHG4 protein (Swiss Prot Ace. No. Q8TC63) or immunoglobulin lambda heavy chain. Other marker proteins are also disclosed.

    Abstract translation: 本发明涉及一种诊断取自人类受试者的有效身体组织的诊断样品中的vCJD的方法，其包括检测诊断样品中蛋白质浓度与 （SwissProt登录号P60709），载脂蛋白A-IV前体（SwissProt登录号P06727）;和对照人受试者的样品，所述蛋白质是：β-肌动蛋白（SwissProt登录号P60709）。 触珠蛋白β链由残基162-406（SwissProt Acc.No.P00738）组成; 血红蛋白β链（SwissProt Ace.No.P02023）; 或α-1-抗胰蛋白酶（SwissProt登录号P01009）; （C1）抑制剂前体（SwissProt Acc.No.P05155）与正常人类受试者的样品相比，诊断样品中蛋白质的浓度或降低的浓度。 补体成分1的子成分（SwissProt Acc.No.P09871）; 丁酰胆碱酯酶前体（SwissProt Acc.No.P06276）; 补体成分C4B（SwissProt Acc.No.P01028）; lumican（SwissProt Ace。No. P51884）; α-纤维蛋白原前体（SwissProt登录号P02671）; IGHG4蛋白（Swiss Prot Ace No.Q8TC63）或免疫球蛋白λ重链。 其他标记蛋白也被公开。

Patent Agency Ranking